| Similar Articles |
|---|
 |
The Motley Fool
January 11, 2012
Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running.   |
The Motley Fool
November 11, 2009
Brian Orelli |
Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown. |
The Motley Fool
January 10, 2012
Travis Hoium |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of Regeneron Pharmaceuticals jumped 13% today after the company said sales of Eylea were strong in the fourth quarter. |
The Motley Fool
September 2, 2011
Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. |
BusinessWeek
September 19, 2005 |
Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
November 23, 2010
Brian Orelli |
Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients. |
The Motley Fool
August 18, 2011
Brian Orelli |
A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
Chemistry World
October 23, 2014
Rebecca Trager |
Amgen seeks injunction to protect patents The US biopharmaceutical company Amgen has filed a patent infringement lawsuit against Sanofi and Regeneron in the US District Court of Delaware. |
The Motley Fool
June 20, 2011
Brian Orelli |
See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
November 21, 2011
Brian Orelli |
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
